{"TopicDetails": {"type": 0, "ccm2Id": 31094169, "cftId": 0, "identifier": "IMI2-2018-14-02", "title": "Non-invasive clinical molecular imaging of immune cells", "publicationDateLong": 1521072000000, "callIdentifier": "H2020-JTI-IMI2-2018-14-two-stage", "callTitle": "H2020-JTI-IMI2-2018-14-two-stage", "callccm2Id": 31094171, "allowPartnerSearch": true, "workProgrammepart": {"id": 267551, "ccm_id": 31095847, "wp_part": "H2020-JTI-IMI-2018", "wp_year": "H2020-JTI-IMI-2018", "wp_title": "H2020-JTI-IMI-2018", "wp_website": "http://www.imi.europa.eu/", "wp_document": "http://ec.europa.eu/research/participants/data/ref/h2020/other/wp/jtis/h2020-wp18-imi2_en.pdf"}, "frameworkProgramme": {"id": 31045243, "abbreviation": "H2020", "description": "Horizon 2020 Framework Programme"}, "programmeDivision": [{"id": 31047894, "abbreviation": "EU.3.1.", "description": "Health, demographic change and wellbeing"}, {"id": 31047893, "abbreviation": "EU.3.", "description": "Societal Challenges"}, {"id": 31062059, "abbreviation": "EU.3.1.7.", "description": "Innovative Medicines Initiative 2 (IMI2)"}, {"id": 31045244, "abbreviation": "EC", "description": "EC Treaty"}], "topicMGAs": [], "tags": ["Joint Undertaking", "immunotracers", "Clinical trials", "Pharmacodynamic (PD)", "immune cells", "IMI", "IMI2", "Innovative Medicines Initiative"], "keywords": ["Patient stratification", "Diagnostic tools (e.g. genetic, imaging)", "Immunology"], "sme": false, "actions": [{"status": {"id": 31094503, "abbreviation": "Closed", "description": "Closed"}, "types": [{"typeOfAction": "IMI2-RIA Research and Innovation action", "typeOfMGA": []}], "plannedOpeningDate": "15 March 2018", "submissionProcedure": {"id": 31094505, "abbreviation": "two-stage", "description": "two-stage"}, "deadlineDates": ["14 June 2018", "11 December 2018"]}], "latestInfos": [], "budgetOverviewJSONItem": {"budgetTopicActionMap": {"3237242": [{"action": "IMI2-2018-14-03 - IMI2-RIA Research and Innovation action", "plannedOpeningDate": "15 March 2018", "deadlineModel": "two-stage", "deadlineDates": ["14 June 2018", "11 December 2018"], "budgetYearMap": {"2018": 167277360}, "budgetTopicActionMap": {}}, {"action": "IMI2-2018-14-04 - IMI2-RIA Research and Innovation action", "plannedOpeningDate": "15 March 2018", "deadlineModel": "two-stage", "deadlineDates": ["14 June 2018", "11 December 2018"], "budgetYearMap": {"2018": 167277360}, "budgetTopicActionMap": {}}, {"action": "IMI2-2018-14-02 - IMI2-RIA Research and Innovation action", "plannedOpeningDate": "15 March 2018", "deadlineModel": "two-stage", "deadlineDates": ["14 June 2018", "11 December 2018"], "budgetYearMap": {"2018": 167277360}, "budgetTopicActionMap": {}}, {"action": "IMI2-2018-14-01 - IMI2-RIA Research and Innovation action", "plannedOpeningDate": "15 March 2018", "deadlineModel": "two-stage", "deadlineDates": ["14 June 2018", "11 December 2018"], "budgetYearMap": {"2018": 167277360}, "budgetTopicActionMap": {}}]}, "budgetYearsColumns": ["2018"]}, "description": "<SPAN class=\"topicdescriptionkind\">Specific Challenge</SPAN>:<p><strong><u>For full details of the topic, please refer to the call text</u></strong></p><p>Current pharmacodynamic (PD) assessments of immune cells are based on peripheral blood biomarkers, or from biopsy samples which are acquired by invasive procedures. Some existing medical imaging modalities provide a quantifiable, non-invasive, repeatable and localised measure of biological processes in the living body. However, current methodology and technology provides limited information on time-dependent and disease-specific relevant immune cell subpopulations and compartments types, or measures of direct engagement of immune targets.</p><p>Imaging tracers designed to bind specific immune cells (\u2018immunotracers\u2019) or targets within immune-mediated pathways would enable the clinical imaging of the target immune cell subtypes and immune markers of disease in a clinical setting, which in turn would provide in vivo insights into effects of immunomodulatory therapies at disease sites (organs/tissues) and improve knowledge about the pathophysiology of various immune-mediated diseases.</p><p>Molecular imaging agents, (hybrid) imaging modalities, and image processing algorithms to image immune cells in vivo are advancing within the imaging field and can provide an immediate, non-invasive read-out of target expression over time. However, further novel imaging agents and technologies will need to be developed in order to extend the applicability of immune cell imaging to additional disease areas, additional tissue sites, and/or immune cell subpopulations especially by increasing the specificity of imaging agents. Therefore, there remains a need to better understand the currently available markers and validate them extensively for clinical use.</p>\n<SPAN class=\"topicdescriptionkind\">Scope</SPAN>:<p><strong><u>For full details of the topic, please refer to the call text</u></strong></p><p>This topic aims to establish a consortium that can develop and validate a quantitative, non-invasive, immune cell imaging platform, which includes novel and target-specific molecular imaging agents, (hybrid) imaging modalities, and image processing algorithms. The topic aligns with the IMI2 Strategic Research Agenda, as it aims to validate immune cell targets based on human biology and to facilitate precision medicine by identification and stratification of patients and prediction of therapeutic outcomes. In addition, it is expected that these agents will facilitate early diagnosis of the disease and/or classification of disease based on the immune phenotype.</p>\n<SPAN class=\"topicdescriptionkind\">Expected Impact</SPAN>:<p><strong><u>For full details of the topic, please refer to the call text</u></strong>.</p><p>Molecular imaging of immune cells could provide an early indicator of whether patients are likely to benefit from a given (immuno-) therapeutic intervention (surrogate of response). The technology to be delivered is expected to have the potential to also provide information for tissue/organ sites that are not biopsy-accessible, thus representing a significant advance in the assessment of the immune marker status for the relevant indications. Patients can be stratified by marker expression, with the potential to offer the most appropriate treatment and thereby reduce the implementation of treatment regimens that are unlikely to be efficacious and would therefore have a negative benefit-risk profile for the individual patient (personalised </p><p>By visualising and quantifying the impact of therapy on specific target sites and related immune-mediated pathways, the planned technology is also expected to reduce ambiguity in the evaluation of efficacy during clinical trials (e.g. provide early indications of patient responses, assessment of variability between and within individuals, facilitate proof of mechanism (POM) and proof of concept (POC) studies of new mechanisms). Spatio-temporal complexity can be studied due to longitudinal imaging capabilities.</p><p>Furthermore, it will have significant impact on personalised approaches to detect and better monitor these diseases already in the early and better treatable stages. It will support and guide physicians and patients in determining the most appropriate care, leading to improved efficiency in the health care system and patient benefits. It is envisioned that the topic will ultimately result in the regulatory acceptance of standardised protocols with validated immune-imaging approaches. Consequently, those approaches will significantly reduce the time and cost of clinical trials.</p><p>Small and medium-sized enterprises (SMEs) can be of great benefit to IMI2 JU projects. Their involvement in the action might offer a complementary perspective to industry and academia, and help deliver the long-term impact of the project.</p>\n", "conditions": "<p class=\"MsoNormal\" style=\"mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;&#10;line-height:normal\"><b><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">Please read carefully all provisions below before the preparation of your application.<o:p></o:p></span></b></p>\r\n<p class=\"MsoNormal\" style=\"mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;&#10;line-height:normal\"><b><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">The IMI2 JU 14th Call for proposals topics text as well as the Call Conditions are available </span></b><b><u><span style=\"font-size:9.0pt;font-family:&#10;&quot;Arial&quot;,sans-serif;mso-fareast-font-family:&quot;Times New Roman&quot;;color:blue;&#10;mso-fareast-language:EN-GB\"><a href=\"https://ec.europa.eu/research/participants/data/ref/h2020/other/call_fiches/jtis/h2020-call-fiche18-14-imi2-ju_en.pdf\" target=\"_blank\">here</a></span></u></b><b><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">.&nbsp;</span></b></p>\r\n<p class=\"MsoNormal\" style=\"mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;&#10;line-height:normal\"><b><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">The budget breakdown for this Call is given at the end of the Call topics text, in the </span></b><b><u><span style=\"font-size:9.0pt;font-family:&#10;&quot;Arial&quot;,sans-serif;mso-fareast-font-family:&quot;Times New Roman&quot;;color:blue;&#10;mso-fareast-language:EN-GB\"><a href=\"https://ec.europa.eu/research/participants/data/ref/h2020/other/call_fiches/jtis/h2020-call-fiche18-14-imi2-ju_en.pdf\" target=\"_blank\">Call Conditions</a></span></u></b><b><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\"> section, as well as the following information :&nbsp;</span></b></p>\r\n<p class=\"MsoNormal\" style=\"mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;&#10;line-height:normal\">&nbsp;</p>\r\n<p class=\"MsoNormal\" style=\"mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;&#10;line-height:normal\"><b><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\"><o:p></o:p></span></b></p>\r\n<p><span style=\"color: rgb(0, 51, 102);\"><strong>1.&nbsp;&nbsp; Eligible countries:</strong></span> described in article 10(2) of the <a href=\"https://ec.europa.eu/research/participants/data/ref/h2020/legal_basis/rules_participation/h2020-rules-participation_en.pdf\" target=\"_blank\">Rules for participation in  Horizon 2020</a> and in article 1 of the <a href=\"http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32014R0622\" target=\"_blank\">Commission Delegated Regulation related to IMI JU</a>.</p>\r\n<p>&nbsp;</p>\n<p><span style=\"color: rgb(0, 51, 102);\"><strong>2.&nbsp;&nbsp; Eligibility and admissibility conditions:</strong></span> described in the <strong><a href=\"https://ec.europa.eu/research/participants/data/ref/h2020/other/guides_for_applicants/jtis/h2020-guide-pse-imi-ju-v1.6_en.pdf\" target=\"_blank\">IMI2 Manual for evaluation, submission and grant award</a>.</strong>  See also the <a href=\"http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32014R0622\" target=\"_blank\">Commission Delegated Regulation related to IMI JU</a>.</p>\r\n<p>&nbsp;</p>\n<p><span style=\"color: rgb(0, 51, 102);\"><strong>Proposal page limits and layout:</strong></span> Please refer to Part B of the proposal template in the submission tool below.</p>\r\n<p>&nbsp;</p>\n<p><span style=\"color: rgb(0, 51, 102);\"><strong>3.&nbsp;&nbsp; Evaluation: </strong></span><br />\r\nSubmission and evaluation process, including evaluation criteria and procedure, scoring and threshold are described in the <strong><a href=\"https://ec.europa.eu/research/participants/data/ref/h2020/other/guides_for_applicants/jtis/h2020-guide-pse-imi-ju-v1.6_en.pdf\" target=\"_blank\">IMI2 Manual for submission, evaluation and grant award</a></strong>. See also the proposal templates for your specific action in section 5, below.</p>\r\n<p>&nbsp;</p>\n<p><span style=\"color: rgb(0, 51, 102);\"><strong>4.&nbsp;&nbsp; Indicative time for evaluation and grant agreement: </strong></span><br />\r\nNotification of outcomes of stage 1 evaluations: maximum 5 months from deadline for submitting proposals.<br />\r\nNotification of outcomes of stage 2 evaluations: maximum 5 months from deadline for submitting full proposals.</p>\r\n<p>Signature of grant agreements: maximum 3 months from the date of informing successful applicants.</p>\r\n<p>&nbsp;</p>\n<p><span style=\"color: rgb(0, 51, 102);\"><strong>5.&nbsp;&nbsp; Proposal templates, evaluation forms and model grant agreements (MGA):</strong></span></p>\r\n<p><strong>IMI2 Research and Innovation Action (IMI2-RIA) </strong><strong>and Innovation Action (IMI2-IA):</strong></p>\r\n<p>Proposal templates are available after entering the submission tool<br />\r\n<br />\r\n<a href=\"https://ec.europa.eu/research/participants/data/ref/h2020/other/call_ptef/ef/h2020-call-ef-imi2-ria-ia-2016_en.pdf\" target=\"_blank\"> Standard evaluation form</a></p>\r\n<p><a href=\"https://ec.europa.eu/research/participants/data/ref/h2020/other/mga/jtis/h2020-mga-imi_en.pdf\" target=\"_blank\">IMI2 Model Grant Agreement</a></p>\r\n<p><a href=\"https://ec.europa.eu/research/participants/data/ref/h2020/other/legal/templ/h2020_tmpl-clinical-studies_2018-2020_en.pdf\" target=\"_blank\">Clinical trial template</a>&nbsp;&ndash; the Clinical Trial template is compulsory at stage 2 only !</p>\r\n<p>&nbsp;</p>\n<p><strong><span style=\"color: rgb(0, 51, 102);\">6.&nbsp;&nbsp; Open access must be granted to all scientific publications </span></strong>resulting from Horizon 2020 actions.</p>\r\n<p>Where relevant, proposals should also provide information on how the  participants will manage the research data generated and/or collected  during the project, such as details on what types of data the project  will generate, whether and how this data will be exploited or made  accessible for verification and re-use, and how it will be curated and  preserved.</p>\r\n<p><span style=\"color: rgb(0, 51, 102);\"><strong>Open access to research data</strong></span><br />\r\nThe Open Research Data Pilot has been extended to cover all Horizon 2020  topics for which the submission is opened on 26 July 2016 or later.  Projects funded under this topic will therefore by default provide open  access to the research data they generate, except if they decide to  opt-out under the conditions described in <a href=\"https://ec.europa.eu/research/participants/data/ref/h2020/other/wp/2018-2020/annexes/h2020-wp1820-annex-l-openaccess_en.pdf\" target=\"_blank\">Annex L of the H2020 main Work Programme</a>. Projects can opt-out at any stage, that is both before and after the grant signature.</p>\r\n<p>Note that the evaluation phase proposals will not be evaluated more  favourably because they plan to open or share their data, and will not  be penalised for opting out.</p>\r\n<p>Open research data sharing applies to the data needed to validate the  results presented in scientific publications. Additionally, projects  can choose to make other data available open access and need to describe  their approach in a Data Management Plan.</p>\r\n<p>Projects need to create a Data Management Plan (DMP), except if they  opt-out of making their research data open access. A first version of  the DMP must be provided as an early deliverable within six months of  the project and should be updated during the project as appropriate. The  Commission already provides guidance documents, including a template  for DMPs. See the <a href=\"https://ec.europa.eu/research/participants/docs/h2020-funding-guide/cross-cutting-issues/open-access-dissemination_en.htm\" target=\"_blank\">Online Manual</a>.</p>\r\n<p>Eligibility of costs: costs related to data management and data  sharing are eligible for reimbursement during the project duration.</p>\r\n<p>The legal requirements for projects participating in this pilot are in the article 29.3 of the Model Grant Agreement.</p>\r\n<p>&nbsp;</p>\n<p>Members of consortium are required to conclude a consortium agreement prior to the signature of the grant agreement.</p>\n<p><span style=\"color: rgb(0, 51, 102);\"><strong>7. Additional documents:</strong></span></p>\r\n<p><a href=\"https://ec.europa.eu/research/participants/data/ref/h2020/other/guides_for_applicants/jtis/h2020-guide-rel-prov-imi-ju_en.pdf\" target=\"_blank\">Summary of the most relevant provisions for participating in IMI2 actions</a></p>\r\n<p><a href=\"https://ec.europa.eu/research/participants/data/ref/h2020/other/wp/jtis/h2020-wp18-imi2-amend-1_en.pdf\" target=\"_blank\">IMI2 Amended Annual Work Plan 2018</a></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt;line-height:&#10;normal\"><a href=\"https://ec.europa.eu/research/participants/data/ref/h2020/other/mga/jtis/h2020-amga-imi_en.pdf\" target=\"_blank\">IMI2 JU Annotated Model Grant Agreement</a><o:p></o:p></p>\r\n<p><a href=\"http://www.imi.europa.eu/sites/default/files/uploads/documents/apply-for-funding/call-documents/imi2/RegulatoryRequirementsGuide.pdf\" target=\"_blank\">IMI2 Regulators Guidance tool for researchers</a></p>\r\n<p><a href=\"http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=OJ:JOL_2014_174_R_0003\" target=\"_blank\">IMI JU derogation to H2020 Rules for Participation</a> &nbsp;<br />\r\n<br />\r\n<a href=\"https://ec.europa.eu/research/participants/data/ref/h2020/legal_basis/rules_participation/h2020-rules-participation_en.pdf\" target=\"_blank\">Horizon 2020 Rules for Participation&nbsp;</a></p>\r\n<p><a href=\"https://ec.europa.eu/research/participants/data/ref/h2020/legal_basis/fp/h2020-eu-establact_en.pdf\" target=\"_blank\">Horizon 2020 Regulation of Establishment </a><br />\r\n<br />\r\n<a href=\"https://ec.europa.eu/research/participants/data/ref/h2020/legal_basis/sp/h2020-sp_en.pdf\" target=\"_blank\">Horizon 2020 Specific Programme</a></p>\r\n<p>&nbsp;</p>", "supportInfo": "<p><span style=\"color: rgb(0, 51, 102);\"><a href=\"http://ec.europa.eu/research/participants/docs/h2020-funding-guide/index_en.htm\" target=\"_blank\"><strong>H2020 Online Manual</strong></a> </span>is your guide on the procedures from proposal submission to managing your grant.</p>\r\n<p><a href=\"http://ec.europa.eu/research/participants/portal/desktop/en/support/faq.html#c,faqs=categoryMachineName/t/pp_roles_and_rights/0/1/1/category&amp;categoryMachineName/t/p_registration/0/1/1/category&amp;categoryMachineName/t/work_programme_calls/0/1/1/category&amp;categoryMachineName/t/p_submission_eval/1/1/1/category&amp;categoryMachineName/t/ethics_research_integrity/0/1/1/category&amp;categoryMachineName/t/grants/0/1/1/category&amp;categoryMachineName/t/audit/0/1/1/category&amp;categoryMachineName/t/experts/0/1/1/category&amp;categoryMachineName/t/eu_research_policy/0/1/1/category&amp;programmeList/t/H2020/0/1/1/programme&amp;programmeList/t/3rd_health_programme/0/1/1/programme&amp;programmeList/t/asylum_migration_and_integration_fund/0/1/1/programme&amp;programmeList/t/consumer_programme/0/1/1/programme&amp;programmeList/t/COSME/0/1/1/programme&amp;programmeList/t/creative_europe_programme/0/1/1/programme&amp;programmeList/t/erasmus_programme/0/1/1/programme&amp;programmeList/t/FP7/0/1/1/programme&amp;programmeList/t/hercule_iii_programme/0/1/1/programme&amp;programmeList/t/internal_security_fund_borders/0/1/1/programme&amp;programmeList/t/internal_security_fund_police/0/1/1/programme&amp;programmeList/t/justice_programme/0/1/1/programme&amp;programmeList/t/pilot_projects_preparatory_actions/0/1/1/programme&amp;programmeList/t/promotion_of_agricultural_products/0/1/1/programme&amp;programmeList/t/research_fund_for_coal_and_steel/0/1/1/programme&amp;programmeList/t/rights_equality_and_citizenship_programme/0/1/1/programme&amp;programmeList/t/union_civil_protection_mechanism/0/1/1/programme&amp;programmeList/t/european_statistics/0/1/1/programme&amp;tagList/t/MSCA/0/1/1/tag&amp;tagList/t/ERC/0/1/1/tag\" target=\"_blank\"><strong><span style=\"color: rgb(0, 51, 102);\">Participant Portal FAQ</span></strong></a> &ndash; Submission of proposals.</p>\r\n<p><a href=\"http://ec.europa.eu/research/participants/portal4/desktop/en/support/national_contact_points.html\" target=\"_blank\"><span style=\"color: rgb(0, 51, 102);\"><strong>National Contact Points (NCP)</strong></span></a> - contact your NCP for further assistance in your national language(s).</p>\r\n<p><a href=\"http://ec.europa.eu/research/index.cfm?lg=en&amp;pg=enquiries\" target=\"_blank\"><span style=\"color: rgb(0, 51, 102);\"><strong>Research Enquiry Service</strong></span></a> &ndash; ask questions about any aspect of European research in general and the EU Research Framework Programmes in particular.</p>\r\n<p><span style=\"color: rgb(0, 51, 102);\"><strong><a href=\"http://een.ec.europa.eu/\" target=\"_blank\">Enterprise Europe Network</a> </strong></span>&ndash; contact your EEN national contact for advice to businesses with special focus on SMEs. The support includes guidance on the EU research funding.</p>\r\n<p><a href=\"http://ec.europa.eu/research/participants/api/contact/index.html\" target=\"_blank\"><span style=\"color: rgb(0, 51, 102);\"><strong>IT Helpdesk</strong></span></a><strong> </strong>- contact the Participant Portal IT helpdesk for questions such as forgotten passwords, access rights and roles, technical aspects of submission of proposals, etc.</p>\r\n<p><span style=\"color: rgb(0, 51, 102);\"><strong>Ethics</strong></span> &ndash; for compliance with ethical issues, see the <a href=\"http://ec.europa.eu/research/participants/docs/h2020-funding-guide/cross-cutting-issues/ethics_en.htm\" target=\"_blank\">Online Manual</a> and <a href=\"http://ec.europa.eu/research/swafs/index.cfm?pg=policy&amp;lib=ethics\" target=\"_blank\">Science and Society Portal</a></p>\r\n<p><a href=\"http://www.iprhelpdesk.eu/\" target=\"_blank\"><span style=\"color: rgb(0, 51, 102);\"><strong>European IPR Helpdesk</strong></span></a> assists you on intellectual property issues</p>\r\n<p><a href=\"https://www.cencenelec.eu/research/Pages/default.aspx\" target=\"_blank\"><span style=\"color: rgb(0, 51, 102);\"><strong>CEN</strong></span><strong> <span style=\"color: rgb(0, 51, 102);\">and</span> </strong><span style=\"color: rgb(0, 51, 102);\"><strong>CENELEC</strong></span></a>, the <span style=\"color: rgb(0, 51, 102);\"><strong>European Standards Organisations</strong></span>, advise you how to tackle standardisation in your project proposal. Contact CEN-CENELEC Research Helpdesk at <span style=\"color: rgb(0, 0, 255);\">research@cencenelec.eu</span></p>\r\n<p><a href=\"http://ec.europa.eu/euraxess/pdf/brochure_rights/am509774CEE_EN_E4.pdf\" target=\"_blank\"><span style=\"color: rgb(0, 51, 102);\"><strong>The European Charter for Researchers and the Code of Conduct for their recruitment</strong></span></a></p>\r\n<p><a href=\"http://ec.europa.eu/research/participants/docs/h2020-funding-guide/grants/applying-for-funding/find-partners_en.htm\" target=\"_blank\"><span style=\"color: rgb(0, 51, 102);\"><strong>Partner Search Services</strong></span></a> help you find a partner organisation for your proposal.</p>\r\n<p><span style=\"font-size:10.0pt;mso-bidi-font-size:11.0pt;font-family:&#10;&quot;Arial&quot;,sans-serif\"><a href=\"http://www.imi.europa.eu/content/states-representatives-groups\"><b><span style=\"background:white\">IMI2 States Representative Group (SRG)</span></b></a><span style=\"color:black;background:white\"><span style=\"font-variant-ligatures: normal;&#10;font-variant-caps: normal;orphans: 2;text-align:start;widows: 2;-webkit-text-stroke-width: 0px;&#10;text-decoration-style: initial;text-decoration-color: initial;float:none;&#10;word-spacing:0px\">&nbsp;&ndash; contact you SRG member for assistance.</span></span><span style=\"color:black\"><br style=\"font-variant-ligatures: normal;font-variant-caps: normal;&#10;orphans: 2;text-align:start;widows: 2;-webkit-text-stroke-width: 0px;&#10;text-decoration-style: initial;text-decoration-color: initial;word-spacing:&#10;0px\" />\r\n<b style=\"font-variant-ligatures: normal;font-variant-caps: normal;orphans: 2;&#10;text-align:start;widows: 2;-webkit-text-stroke-width: 0px;text-decoration-style: initial;&#10;text-decoration-color: initial;word-spacing:0px\"><span style=\"background:white\"><br />\r\n<a href=\"mailto:applicants@imi.europa.eu\" target=\"_blank\"> IMI2 JU&nbsp;</a></span></b></span><b style=\"font-variant-ligatures: normal; font-variant-caps: normal; orphans: 2; text-align: start; widows: 2; -webkit-text-stroke-width: 0px; word-spacing: 0px;\"><span style=\"background:white\"><a href=\"mailto:applicants@imi.europa.eu\" target=\"_blank\">Applicants Helpdesk</a></span></b><span style=\"color:black;background:white\"><span style=\"font-variant-ligatures: normal;&#10;font-variant-caps: normal;orphans: 2;text-align:start;widows: 2;-webkit-text-stroke-width: 0px;&#10;text-decoration-style: initial;text-decoration-color: initial;float:none;&#10;word-spacing:0px\">&nbsp;&ndash; c</span><strong style=\"font-variant-ligatures: normal;&#10;font-variant-caps: normal;orphans: 2;text-align:start;widows: 2;-webkit-text-stroke-width: 0px;&#10;text-decoration-style: initial;text-decoration-color: initial;word-spacing:&#10;0px\"><span style=\"font-family:&quot;Arial&quot;,sans-serif;font-weight:normal\">ontact the IMI2 Programme Office</span></strong></span><o:p></o:p></span></p>\r\n<p>&nbsp;</p>", "sepTemplate": "<p>To access the Electronic Submission Service of the topic, please select the <strong>type of action</strong> that is most relevant to your proposal from the list below and click on the <strong>'Start Submission' </strong>button. You will then be asked to confirm your choice of the type of action and topic, as these cannot be changed in the submission system. Upon confirmation you will be linked to the correct entry point.</p>\r\n<p>To access existing draft proposals for this topic, please login to the Participant Portal and select the My Proposals page of the My Area section.</p>", "links": [], "additionalDossiers": [{"callId": 52392605851, "id": 165889892, "title": "IMI2 Call 14 stage 2 - Flash Call Info Report ", "sectionId": 52392605851, "translationFiles": [{"language": "en", "mimeType": "application/pdf", "fileSize": 247916, "docPath": "https://ec.europa.eu/info/funding-tenders/opportunities/docs/cap/h2020/imi2-2018-14-02/1847620-imi2_call_14_flash_call_info_report_stage_2_en.pdf", "id": 1847620, "fileName": "IMI2 Call 14_Flash Call Info report_Stage 2_EN.pdf", "common": false, "crc32": 2579013991}]}], "infoPackDossiers": [], "callDetailsJSONItem": {"latestInfos": [{"approvalDate": "Feb 20, 2019 11:10:39 AM", "lastChangeDate": "Feb 20, 2019 11:10:39 AM", "content": "<p>An overview of the evaluation results (<a href=\"http://ec.europa.eu/research/participants/portal/doc/call/h2020/imi2-2018-14-01/1847620-imi2_call_14_flash_call_info_report_stage_2_en.pdf\" target=\"_blank\">flash call info &ndash; IMI2 Call 14 &ndash; stage two</a>) is now available under the call &lsquo;Additional documents&rsquo; tab.</p>\r\n<p>&nbsp;</p>\r\n<p>&nbsp;</p>"}, {"approvalDate": "Aug 13, 2018 4:04:24 PM", "lastChangeDate": "Aug 13, 2018 4:04:24 PM", "content": "<p><font face=\"Verdana, Geneva, sans-serif\"><span style=\"font-size: 12.1px; background-color: rgb(198, 219, 239);\">An overview of the evaluation results (<a href=\"http://ec.europa.eu/research/participants/portal/doc/call/h2020/imi2-2018-14-01/1835109-imi2_call_14_-_flash_call_info_report_-_stage_1_en.pdf\" target=\"_blank\">flash call info &ndash; IMI2 Call 14 &ndash; stage one</a>) is now available under the call &lsquo;Additional documents&rsquo; tab.</span></font></p>"}, {"approvalDate": "Jun 18, 2018 4:31:03 PM", "lastChangeDate": "Jun 18, 2018 4:31:03 PM", "content": "<p><strong>Proposal numbers</strong></p>\r\n<p>Stage 1 submission deadline for the Call<strong> IMI2-2018-14-two-stage </strong>has closed on the <strong>14 June 2018.</strong></p>\r\n<p>28 proposals have been submitted.</p>\r\n<p>The breakdown per topic is:</p>\r\n<p>IMI2-2018-14-01: 12</p>\r\n<p>IMI2-2018-14-02:&nbsp;&nbsp; 3</p>\r\n<p>IMI2-2018-14-03:&nbsp;&nbsp; 9</p>\r\n<p>IMI2-2018-14-04:&nbsp; 4</p>\r\n<div style=\"margin: 0cm 0cm 8pt\">Evaluation results for stage 1 are expected to be communicated in the second part of August 2018.</div>"}, {"approvalDate": "Mar 15, 2018 12:30:00 AM", "lastChangeDate": "Mar 15, 2018 12:30:00 AM", "content": "The submission session is now available for: IMI2-2018-14-01(IMI2-RIA), IMI2-2018-14-02(IMI2-RIA), IMI2-2018-14-03(IMI2-RIA), IMI2-2018-14-04(IMI2-RIA)"}], "hasForthcomingTopics": false, "hasOpenTopics": false, "allClosedTopics": true}}}